Metahexamide
![]() | |
| Names | |
|---|---|
| IUPAC name
1-(3-amino-4-methylphenyl)sulfonyl-3-cyclohexylurea | |
| Identifiers | |
| 565-33-3 | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL507419 |
| ChemSpider | 10785 |
| ECHA InfoCard | 100.008.434 |
| KEGG | D07117 |
| PubChem | 11259 |
| UNII | T3U6F5D722 |
| |
| |
| Properties | |
| C14H21N3O3S | |
| Molar mass | 311.4 g/mol |
| Pharmacology | |
| A10BB10 (WHO) | |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| | |
| Infobox references | |
Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
References
- ↑ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
